|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, this review summarizes these recent findings for the efficacy of two of the most widely used antihypertensive drug classes, ACE inhibitors and ARBs, to reduce or treat inflammatory diseases such as atherosclerosis, arthritis, steatohepatitis, colitis, pancreatitis, and nephritis.
|
30191985 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we sought to assess the impact of myeloid ACE on atherosclerosis.
|
31615657 |
2019 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Alu polymorphism of angiotensin I converting enzyme (ACE) and atherosclerosis, incident chronic diseases and mortality in an elderly Chinese population.
|
22456784 |
2012 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of monocytic angiotensin-converting enzyme (ACE) found in haemodialysis (HD) patients may directly participate in the pathogenesis of atherosclerosis.
|
28186543 |
2017 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The eNOS G894T and ACE I/D polymorphisms are associated with an increased risk of developing ACS after adjusting for classical risk factors for atherosclerosis in the Bulgarian cohort.
|
26670794 |
2016 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study indicated that patients with atherosclerosis had higher levels of oxidized Low-Density Lipoprotein (oxLDL) and ACE activity (P < 0.05) as compared to controls.
|
31370787 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data provide another important mechanism by which inflammation associated with increased ACE expression may contribute to the progression of atherosclerosis.
|
10642324 |
2000 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Early sign of atherosclerosis in slow coronary flow and relationship with angiotensin-converting enzyme I/D polymorphism.
|
17285438 |
2007 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Insertion/deletion polymorphism in ACE gene (ACE I/D) is known to be associated with the occurrence of ischaemic stroke through its effect on pathogenesis of atherosclerosis and hypertension.
|
29199539 |
2018 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It has been suggested that angiotensin converting enzyme insertion/deletion polymorphism is associated with atherosclerosis.
|
17611909 |
2007 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative analysis of immunoreactivity showed that total vessel wall expression of ACE and ACE2 was similar during all stages of atherosclerosis.
|
18498093 |
2008 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To identify anti-atherogenic target genes, we performed microarray gene expression profiling of the aorta during atherosclerosis prevention with the ACE inhibitor, captopril.
|
20504763 |
2010 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The basic factor of cardiovascular diseases is atherosclerosis, which is due largely to an increase in the activity of the angiotensin-converting enzyme (ACE) in vessels.
|
30148999 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin I-converting enzyme (ACE), which plays an important role in blood pressure regulation, and methylenetetrahydrofolate reductase (MTHFR) involved in homocysteine metabolism belong to a large group of polypeptides which may be potential risk factors for atherosclerosis and coronary artery disease (CAD).
|
12833177 |
2003 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The hypothesis that genetic variation in the level of ACE gene expression affects the development of atherosclerosis is not supported by these findings.
|
9261253 |
1997 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin I converting enzyme (ACE) insertion/deletion (I/D) polymorphism is thought to affect renin-angiotensin system (RAS) activity and development of cardiovascular disease; significant associations between I/D polymorphism and atherosclerosis, stroke, nephropathy, and early mortality were already found.
|
28190172 |
2017 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chronic exposure to high levels of circulating and tissue ACE predispose to vascular wall thickening and atherosclerosis.
|
20364300 |
2010 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the influence of apolipoprotein E (APOE) and angiotensin-converting enzyme (ACE) gene polymorphisms on carotid artery atherosclerosis in alcoholism.
|
15809232 |
2005 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACE could affect smooth muscle cell and fibroblast migration and proliferation, low-density lipoprotein (LDL) oxidation and endothelial cell function; these are all important factors in atherosclerosis.
|
9200271 |
1997 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is assumed that the excess supply of angiotensin II (due to the deletion polymorphism of the angiotensin-converting enzyme gene) contributes to endothelial dysfunction and in this way promotes the onset and progression of atherosclerosis.
|
12143941 |
2002 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Regarding pre-hospital medications, atherosclerosis-AHF patients were more likely to be administered nitroglycerin (20.3 vs. 13.7%, p = 0.003), nicorandil (18.8 vs. 7.5%, p < 0.001), angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) (46.5 vs. 38.6%, p = 0.006), β-blocker (33.2 vs. 26.6%, p = 0.014) and statin (30.1 vs. 22.4%, p = 0.003) because of a previous coronary event or atherosclerotic diseases.
|
29943232 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, development of antagonists or inhibitors of molecules such as peroxisome proliferator-activated receptors (PPARs), lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), angiotensin-converting enzyme (ACE), angiotensin receptors and tumor necrosis factor (TNF)-alpha could be another alternative to prevent atherosclerosis.
|
19754391 |
2009 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACE can affect oxidation of LDL, endothelial cell function, and smooth muscle cell migration and proliferation: all important components of atherosclerosis.
|
7614074 |
1995 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
|
15123520 |
2004 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of studies in humans looking more directly at the influence of ACE inhibitors on atherosclerosis and ischemic heart disease are awaited.
|
9115957 |
1996 |